UBS made no change to the firm’s Buy rating or $16 price target on shares of Teva. Following meetings with the company’s management, UBS has increased confidence in its fiscal 2024 estimates and continued growth trajectory, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on TEVA:
